Log in

NASDAQ:AKRXAkorn Stock Price, Forecast & News

$0.09
-0.09 (-51.01 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.09
Now: $0.09
$0.20
50-Day Range
$0.09
MA: $0.23
$0.33
52-Week Range
$0.09
Now: $0.09
$5.46
Volume36.14 million shs
Average Volume9.60 million shs
Market Capitalization$11.98 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.
Read More
Akorn logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:AKRX
CUSIP00972810
CIK3116
Phone847-279-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$682.43 million
Cash Flow$0.47 per share
Book Value$1.86 per share

Profitability

Net Income$-226,770,000.00

Miscellaneous

Employees2,227
Market Cap$11.98 million
Next Earnings DateN/A
OptionableOptionable

Receive AKRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter.

Akorn (NASDAQ:AKRX) Frequently Asked Questions

How has Akorn's stock been impacted by COVID-19 (Coronavirus)?

Akorn's stock was trading at $0.7630 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AKRX stock has decreased by 88.2% and is now trading at $0.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Akorn?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Akorn.

How were Akorn's earnings last quarter?

Akorn, Inc. (NASDAQ:AKRX) released its earnings results on Monday, May, 11th. The company reported $0.36 EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.45. The firm earned $204.69 million during the quarter, compared to analyst estimates of $168.90 million. Akorn had a positive return on equity of 8.53% and a negative net margin of 55.64%. View Akorn's earnings history.

What price target have analysts set for AKRX?

2 equities research analysts have issued 12 month price targets for Akorn's stock. Their forecasts range from $2.00 to $4.00. On average, they anticipate Akorn's stock price to reach $3.00 in the next year. This suggests a possible upside of 3,233.3% from the stock's current price. View analysts' price targets for Akorn.

Has Akorn been receiving favorable news coverage?

News coverage about AKRX stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Akorn earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutAkorn.

Are investors shorting Akorn?

Akorn saw a increase in short interest in May. As of May 15th, there was short interest totaling 10,750,000 shares, an increase of 39.1% from the April 30th total of 7,730,000 shares. Based on an average daily trading volume, of 9,290,000 shares, the short-interest ratio is currently 1.2 days. Currently, 9.3% of the company's stock are sold short. View Akorn's Current Options Chain.

Who are some of Akorn's key competitors?

What other stocks do shareholders of Akorn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Who are Akorn's key executives?

Akorn's management team includes the following people:
  • Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
  • Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)
  • Dr. Bruce Kutinsky, Consultant (Age 53)
  • Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)

What is Akorn's stock symbol?

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Who are Akorn's major shareholders?

Akorn's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.32%), State Street Corp (2.36%), AQR Capital Management LLC (1.63%), Two Sigma Advisers LP (1.48%), Invesco Ltd. (1.09%) and Geode Capital Management LLC (1.08%). Company insiders that own Akorn stock include Alan D Weinstein, Christopher Young, Jonathan Kafer, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View institutional ownership trends for Akorn.

Which major investors are selling Akorn stock?

AKRX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Squarepoint Ops LLC, Two Sigma Investments LP, Geode Capital Management LLC, State Street Corp, BlackRock Inc., Spark Investment Management LLC, and GSA Capital Partners LLP. Company insiders that have sold Akorn company stock in the last year include Christopher Young, and Jonathan Kafer. View insider buying and selling activity for Akorn.

Which major investors are buying Akorn stock?

AKRX stock was acquired by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Invesco Ltd., Wells Fargo & Company MN, JPMorgan Chase & Co., and Nuveen Asset Management LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer, and Terry Allison Rappuhn. View insider buying and selling activity for Akorn.

How do I buy shares of Akorn?

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akorn's stock price today?

One share of AKRX stock can currently be purchased for approximately $0.09.

How big of a company is Akorn?

Akorn has a market capitalization of $11.98 million and generates $682.43 million in revenue each year. The company earns $-226,770,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Akorn employs 2,227 workers across the globe.

What is Akorn's official website?

The official website for Akorn is www.akorn.com.

How can I contact Akorn?

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.